L-炔丁基甘氨酸 | 29834-76-2

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 甘氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-炔丁基甘氨酸
• 英文名称: (2S)-2-aminohex-4-ynoate
• 英文别名: (2S)-2-azaniumylhex-4-ynoate
• CAS: 29834-76-2
• 化学式: C6H9NO2
• 分子量: 127.14
• InChiKey: VDWGCMRALYSYJV-YFKPBYRVSA-N

物化性质

• 熔点：
  238-240℃
• 沸点：
  264.4±35.0 °C(Predicted)
• 密度：
  1.160±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• POTENT AND SELECTIVE INHIBITORS OF NAV1.7
  申请人：AMGEN INC

  公开号：US20160024159A1

  公开（公告）日：2016-01-28

  Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Na V 1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Na V 1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

  本文揭示了一种物质组合物，包括一种孤立的多肽，该多肽是一种外周限制的NaV1.7抑制剂。在一些公开的实施方式中，这种孤立的多肽是NaV1.7的抑制剂。其他实施方式是该物质组合物的共轭实施方式和含有该物质组合物的药物组合物。还揭示了编码一些创新多肽的孤立核酸和表达载体以及含有它们的重组宿主细胞。还揭示了一种治疗或预防疼痛的方法。
• INSULIN ANALOGUES
  申请人：Robinson Andrea

  公开号：US20120225811A1

  公开（公告）日：2012-09-06

  A dicarba analogue of insulin comprising an A-chain and a B-chain or fragments, salts, solvates, derivatives, isomers or tautomers of the A-chain, the B-chain or both, provided that the dicarba analogue is not [A7,B7-(2,7-diaminosuberoyl]-des-(B26-B30)-insulin B25-amide.

  一种二卡巴胰岛素类似物，包括A链和B链或其片段，盐，溶剂化合物，衍生物，同分异构体或互变异构体，但前提是该二卡巴类似物不是[A7，B7-（2,7-二氨基戊二酰基）-去除（B26-B30）-胰岛素B25酰胺。
• Potent and selective inhibitors of Nav1.7
  申请人：AMGEN INC.

  公开号：US10344060B2

  公开（公告）日：2019-07-09

  Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

  公开了一种物质组合物，其中包含一种分离多肽，它是一种外周限制性 NaV1.7 抑制剂。在一些已公开的实施方案中，分离的多肽是 NaV1.7 的抑制剂。其他实施方案是本发明物质组合物和含有本发明物质组合物的药物组合物的共轭实施方案。本发明公开了编码本发明多肽的某些实施方案的分离核酸和表达载体，以及含有它们的重组宿主细胞。还公开了一种治疗或预防疼痛的方法。
• Glucose responsive insulins
  申请人：Mahdavi Alborz

  公开号：US11052133B2

  公开（公告）日：2021-07-06

  This disclosure provides a composition containing a conjugate with a modified insulin molecule. The conjugate has an insulin molecule, which can be insulin or an insulin analog, glucagon, GLP-1, GLP-2 or a GLP-1 agonist. The conjugate also contains one or more polymers. Each of the one or more polymers is covalently linked to the insulin molecule. Additionally, each of the one or more polymers is covalently linked to between 0 to 50 copies of a decoy ligand, and to between 0 to 50 copies of a glucose-binding agent, such that the combined total number of glucose-binding agents and decoy ligands covalently linked to each of the one or more polymers is at least 1. The conjugate can reversibly bind to soluble glucose and in which the extent of its glucose-binding controls the extent to which the modified insulin is able to bind to and activate the insulin receptor. Methods of making the conjugate, as well as use of the conjugate in treatment, are also provided.

  本公开提供了一种含有改良胰岛素分子共轭物的组合物。该共轭物含有胰岛素分子，可以是胰岛素或胰岛素类似物、胰高血糖素、GLP-1、GLP-2 或 GLP-1 激动剂。共轭物还含有一种或多种聚合物。每种聚合物都与胰岛素分子共价连接。此外，一种或多种聚合物中的每一种都与 0 至 50 份诱饵配体和 0 至 50 份葡萄糖结合剂共价连接，这样与一种或多种聚合物中的每一种共价连接的葡萄糖结合剂和诱饵配体的总数至少为 1。 该共轭物可与可溶性葡萄糖可逆地结合，其中葡萄糖结合的程度控制着修饰后的胰岛素能够与胰岛素受体结合并激活胰岛素受体的程度。此外，还提供了制造该共轭物的方法以及该共轭物在治疗中的用途。
• METHODS FOR THE SYNTHESIS OF ALKYNE-CONTAINING DICARBA BRIDGES IN PEPTIDES
  申请人：Syngene Limited

  公开号：EP2576588A1

  公开（公告）日：2013-04-10